Leqembi (lecanemab) and Kisunla (donanemab) are proven to slow cognitive and functional decline by 27 and 35%, respectively.

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic ...

Stroke experts from UCSF Health presented new research and clinical findings at the annual the American Stroke Association’s International Stroke Conference (ISC25), the world’s premier meeting ...

The results increase “my confidence that this approach has merit,” Lauren Sansing says. More trials are on the way.

Lifetime history of heavy cannabis use is associated with lower brain activation on working memory tasks among young adults.

Former NFL players Luke Kuechly and Merril Hoge have joined NeuroTech Insights as Special Advisors, bringing their firsthand experience and advocacy for brain health and concussion awareness to the ...

How long does it take to become a physiotherapist? The Bachelor programme takes four years of full-time study. Students are ...

The docuseries has just begun streaming on Amazon Prime Video, with the first two episodes now available. The synopsis reads: ...

Spinocerebellar Ataxia (SCA) is a rare, genetic, life-threatening neurodegenerative disease with no available treatment.Troriluzole demonstrated a 50-70% slowing of SCA disease progression on the ...

IFB-088 (icerguastat) was safe and significantly slowed disease progression in certain people with ALS in a Phase 2 clinical trial.

GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN –– Approval based on positive data ...